Chimeric Endolysin Polypeptide for Resistant Staphylococcus Biofilms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The widespread emergence of antimicrobial resistance in Staphylococcus species, particularly Staphylococcus aureus and Staphylococcus epidermidis, has rendered existing treatments ineffective, with biofilm production complicating infections and limited antibiotic options, necessitating a novel antimicrobial compound with improved activity and stability.
Innovation Solution
A chimeric endolysin polypeptide combining an M23 endopeptidase and a CHAP domain, separated by a specific linker, exhibits enhanced lytic activity against Staphylococcus species, including both coagulase-positive and coagulase-negative strains, with improved stability and activity in human serum.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then bacterial growth can be inhibited, but antibiotic resistance develops and treatment efficacy decreases
Solution Approach 1:
The endolysin polypeptide is divided into distinct functional domains (N-terminal domain, catalytic domain, C-terminal domain) that can independently perform specific functions such as binding to peptidoglycan and catalyzing bond cleavage, allowing targeted action against bacterial cell walls without affecting other cellular processes
Solution Approach 2:
The endolysin polypeptide acts as an intermediary substance that directly targets and degrades bacterial peptidoglycan cell walls, providing a novel mechanism of action that bypasses conventional antibiotic pathways and thereby avoids antibiotic resistance while maintaining treatment efficacy
2Productivity
If endolysins are engineered for enhanced activity, then bacterial cell wall degradation improves, but polypeptide stability and solubility may decrease
Solution Approach 1:
The polypeptide sequence is optimized by modifying amino acid parameters including increasing hydrophilic residues to improve solubility, adjusting charge distribution to enhance stability, and optimizing the balance between catalytic activity and structural stability through systematic parameter adjustment
Solution Approach 2:
The endolysin polypeptide incorporates a composite structure combining a catalytic domain for peptidoglycan degradation with N-terminal and C-terminal domains that provide structural stability and solubility, creating a multi-functional composite polypeptide that balances activity and stability
3Productivity
If endolysin expression is increased to enhance antibacterial effect, then bacterial cell wall degradation accelerates, but production costs and manufacturing complexity increase
Solution Approach 1:
The endolysin polypeptide is designed to be self-expressing and self-active, requiring no complex delivery systems or activation mechanisms, thereby simplifying manufacturing while maintaining high antibacterial efficacy through direct bacterial cell wall degradation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric endolysin polypeptide demonstrates at least 10% enhanced lytic activity against Staphylococcus species, effectively targeting and disrupting bacterial cell walls, offering a potential alternative to traditional antibiotics for treating infections and biofilms.
Implementation Method 1
The chimeric endolysin polypeptides of the present application bind to and degrade peptidoglycan
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The invention relates to the field of medicine, specifically to the field of treatment of conditions associated with Staphylococcus infection. The invention relates to a novel endolysin polypeptide specifically targeting a bacterial Staphylococcus cell. The invention further relates to said endolysin polypeptide for medical use, preferably for treating an individual suffering from a condition associated with Staphylococcus infection.